

Stephen G Swisher

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3870447/stephen-g-swisher-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

193
papers

7,133
citations

44
h-index

80
g-index

206
ext. papers

9,574
ext. citations

5.8
avg, IF

5.41
L-index

#	Paper	IF	Citations
193	Surgical outcomes after nivolumab or nivolumab with ipilimumab treatment in patients with non-small cell lung cancer.. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022 ,	1.5	3
192	Surgical Complexity of Pulmonary Resections Performed for Oligometastatic NSCLC.. <i>JTO Clinical and Research Reports</i> , 2022 , 3, 100288	1.4	
191	Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection.. <i>Lung Cancer</i> , 2022 , 164, 69-75	5.9	0
190	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.. <i>Nature Communications</i> , 2022 , 13, 1797	17.4	0
189	The Role of Surgery in the Treatment of Melanoma Pulmonary Metastases in the Modern Era.. <i>Journal of Surgical Research</i> , 2022 , 277, 125-130	2.5	
188	Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021 , 162, 1404-1412.e25	12.5	8
187	/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition. <i>Clinical Cancer Research</i> , 2021 , 27, 1720-1733	12.9	9
186	Sustained reduction of discharge opioid prescriptions in an enhanced recovery after thoracic surgery program: A multilevel generalized linear model. <i>Surgery</i> , 2021 ,	3.6	1
185	Matched Pairs Comparison of an Enhanced Recovery Pathway Versus Conventional Management on Opioid Exposure and Pain Control in Patients Undergoing Lung Surgery. <i>Annals of Surgery</i> , 2021 , 274, 1099-1106	7.8	10
184	Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. <i>Cancer Cell</i> , 2021 , 39, 346-360.e7	24.3	107
183	Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment. <i>Lung Cancer</i> , 2021 , 154, 76-83	5.9	5
182	Synchronous Esophageal and Lung Cancers-Is Combined Anatomic Resection Appropriate?. <i>Annals of Thoracic Surgery</i> , 2021 ,	2.7	1
181	Robotic Surgery and Anatomic Segmentectomy: An Analysis of Trends, Patient Selection, and Outcomes. <i>Annals of Thoracic Surgery</i> , 2021 ,	2.7	1
180	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 583-600	8.9	18
179	Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 601-609	8.9	11
178	Pulmonary resection for tissue harvest in adoptive tumor-infiltrating lymphocyte therapy: Safety and feasibility. <i>Journal of Surgical Oncology</i> , 2021 , 124, 699-703	2.8	2
177	Impact of genomic aberrations and additional therapies on survival outcomes of patients with operable non-small cell lung cancer (NSCLC) from the NEOSTAR study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 8542-8542	2.2	0

176	Extrapleural Pneumonectomy Versus Pleurectomy/Decortication for Malignant Pleural Mesothelioma. <i>Annals of Thoracic Surgery</i> , 2021 ,	2.7	2
175	Preoperative Maximum Standardized Uptake Value Associated With Recurrence Risk in Early Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2021 ,	2.7	0
174	Modified En Bloc Esophagectomy Compared With Standard Resection After Neoadjuvant Chemoradiation. <i>Annals of Thoracic Surgery</i> , 2021 , 111, 1133-1140	2.7	2
173	Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations. <i>Chest</i> , 2021 , 159, 1256-1264	5.3	5
172	Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 127-139	8.9	14
171	Postoperative Bleeding and Acute Kidney Injury in Esophageal Cancer Patients Receiving Ketorolac. <i>Annals of Thoracic Surgery</i> , 2021 , 111, 1111-1117	2.7	
170	Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy. <i>European Journal of Cardio-thoracic Surgery</i> , 2021 , 59, 100-108	3	5
169	Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. <i>Annals of Surgery</i> , 2021 , 273, 751-757	7.8	4
168	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. <i>Nature Medicine</i> , 2021 , 27, 504-514	50.5	105
167	Intestinal Metaplasia in the Esophageal Remnant Is Rare After Ivor Lewis Esophagectomy. <i>Journal of Gastrointestinal Surgery</i> , 2021 , 25, 2185-2191	3.3	0
166	Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. <i>Nature Communications</i> , 2021 , 12, 5045	17.4	6
165	Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer 2021 , 9,		13
164	Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1289-1297	8.9	6
163	Liposomal Bupivacaine Intercostal Block Is Important for Reduction of Pulmonary Complications. <i>Annals of Thoracic Surgery</i> , 2021 , 112, 423-429	2.7	3
162	Optimizing Discharge After Shorter Hospitalizations: Lessons Learned Through After-Hours Calls with Thoracic Surgical Patients. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2021 , 16, 529-535	1.5	1
161	Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers. <i>Annals of Thoracic Surgery</i> , 2021 ,	2.7	2
160	The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. <i>Nature Communications</i> , 2021 , 12, 7081	17.4	1
159	Barriers to surveillance imaging adherence in early-staged lung cancer.. <i>Journal of Thoracic Disease</i> , 2021 , 13, 6848-6854	2.6	0

158	Single Chest Drain Practice Reduces Discharge Opioid Prescriptions in Thoracic Surgery. <i>Thoracic and Cardiovascular Surgeon</i> , 2021 ,	1.6	1
157	Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. <i>Genome Biology</i> , 2020 , 21, 271	18.3	13
156	Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort 2020 , 8,		13
155	Importance of resection for locoregional disease control in Masaoka stage IVA thymic neoplasms. <i>Journal of Surgical Oncology</i> , 2020 , 122, 515-522	2.8	0
154	Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1569-1579	2.2	70
153	Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. <i>Lung Cancer</i> , 2020 , 146, 303-309	5.9	2
152	Hospital readmissions after pulmonary resection: post-discharge nursing telephone assessment identifies high risk patients. <i>Journal of Thoracic Disease</i> , 2020 , 12, 184-190	2.6	2
151	Genomic assessment distinguishes intrapulmonary metastases from synchronous primary lung cancers. <i>Journal of Thoracic Disease</i> , 2020 , 12, 1952-1959	2.6	4
150	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 709-740	8.9	77
149	High mutational concordance between primary colorectal tumors and associated pulmonary metastases. <i>Journal of Surgical Oncology</i> , 2020 , 121, 984-989	2.8	
148	Development of Miniature Y Stent for Treatment of Postoperative Bronchial Stenosis. <i>Annals of Thoracic Surgery</i> , 2020 , 110, e99-e101	2.7	1
147	Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. <i>Clinical Lung Cancer</i> , 2020 , 21, e294-e301	4.9	4
146	A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 3525-3536	12.9	9
145	Brain metastases in patients with upper gastrointestinal cancer is associated with proximally located adenocarcinoma and lymph node metastases. <i>Gastric Cancer</i> , 2020 , 23, 904-912	7.6	4
144	Time trends and predictors of survival in surgically resected early-stage non-small cell lung cancer patients. <i>Journal of Surgical Oncology</i> , 2020 , 122, 495-505	2.8	5
143	Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. <i>Clinical Lung Cancer</i> , 2020 , 21, 341-348	4.9	27
142	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. <i>Clinical Cancer Research</i> , 2020 , 26, 892-901	12.9	34
141	KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. <i>American Journal of Cancer Research</i> , 2020 , 10, 4464-4475	4.4	3

140	Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1449-1459	8.9	49
139	Comprehensive T cell repertoire characterization of non-small cell lung cancer. <i>Nature Communications</i> , 2020 , 11, 603	17.4	67
138	Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. <i>Nature Cancer</i> , 2020 , 1, 423-436	15.4	88
137	Preoperative Heparin for Lung Cancer Resection Increases Risk of Reoperation for Bleeding. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2020 , 32, 337-343	1.7	4
136	Surveillance After Treatment of Non-Small-Cell Lung Cancer: A Call for Multidisciplinary Standardization. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2020 , 15, 57-65	1.5	3
135	Cancer Surgery Scheduling During and After the COVID-19 First Wave: The MD Anderson Cancer Center Experience. <i>Annals of Surgery</i> , 2020 , 272, e106-e111	7.8	17
134	Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. <i>Clinical Cancer Research</i> , 2020 , 26, 5477-5486	12.9	12
133	Time Trends of Perioperative Outcomes in Early Stage Non-Small Cell Lung Cancer Resection Patients. <i>Annals of Thoracic Surgery</i> , 2020 , 109, 404-411	2.7	6
132	Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2020 , 109, 358-366	2.7	2
131	Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells. <i>Oncogene</i> , 2020 , 39, 801-813	9.2	7
130	Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020 , 21, 37-46.e7	4.9	26
129	F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 1519-1534	7.4	11
128	Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities. <i>Journal of Thoracic Disease</i> , 2020 , 12, 329-337	2.6	1
127	Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. <i>JAMA Oncology</i> , 2019 , 5, 1597-1604	13.4	35
126	Ground Glass Lesions on Chest Imaging: Evaluation of Reported Incidence in Cancer Patients Using Natural Language Processing. <i>Annals of Thoracic Surgery</i> , 2019 , 107, 936-940	2.7	10
125	PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1021-1031	8.9	46
124	Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2019 , 108, 845-851	2.7	5
123	Robotic-Assisted Lobectomy for Non-Small Cell Lung Cancer: A Comprehensive Institutional Experience. <i>Annals of Thoracic Surgery</i> , 2019 , 108, 370-376	2.7	25

122	Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. <i>Nature Communications</i> , 2019 , 10, 2978	17.4	43
121	Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice. <i>Cancer</i> , 2019 , 125, 3738-3748	6.4	13
120	Colorectal cancer mutations are associated with survival and recurrence after pulmonary metastasectomy. <i>Journal of Surgical Oncology</i> , 2019 , 120, 729-735	2.8	9
119	Multidisciplinary treatment of thymic neuroendocrine tumors: surgery remains a key component. <i>Journal of Thoracic Disease</i> , 2019 , 11, 3391-3398	2.6	3
118	Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8504-8504	2.2	80
117	T cell repertoire analysis of non-small cell lung cancer patients treated with neoadjuvant nivolumab alone or in combination with ipilimumab (NEOSTAR trial).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8532-8532	2.2	3
116	Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9017-9017	2.2	7
115	Glutathione reductase () gene deletion and chromosome 8 aneuploidy in primary lung cancers detected by fluorescence in situ hybridization. <i>American Journal of Cancer Research</i> , 2019 , 9, 1201-1211	4.4	1
114	Association of relative neutrophilia with a distinct immunoinhibitory milieu in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14047-e14047	2.2	0
113	Heterogeneity of stage IIIA leads to difficulty in determining optimal treatment. <i>Journal of Thoracic Disease</i> , 2019 , 11, S2043-S2045	2.6	
112	Facilitation of Surgical Innovation: Is It Possible to Speed the Introduction of New Technology While Simultaneously Improving Patient Safety?. <i>Annals of Surgery</i> , 2019 , 270, 937-941	7.8	7
111	Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis. <i>Cancer Research</i> , 2019 , 79, 125-132	10.1	31
110	Applying Artificial Intelligence to Address the Knowledge Gaps in Cancer Care. <i>Oncologist</i> , 2019 , 24, 772-782	5.7	19
109	Surgical margins and risk of local recurrence after wedge resection of colorectal pulmonary metastases. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019 , 157, 1648-1655	1.5	13
108	Multimodality Therapy for N2 Non-Small Cell Lung Cancer: An Evolving Paradigm. <i>Annals of Thoracic Surgery</i> , 2019 , 107, 277-284	2.7	11
107	Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations. <i>Clinical Lung Cancer</i> , 2019 , 20, 30-36.e3	4.9	19
106	Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 150-157	12.9	7
105	Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC). <i>Clinical Lung Cancer</i> , 2019 , 20, 43-47	4.9	32

104	Stereotactic ablative body radiation for oligometastatic and oligoprogressive disease. <i>Translational Lung Cancer Research</i> , 2019 , 8, 97-106	4.4	20
103	Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , 2018 , 53, 960-966	3	13
102	Genetic variants in cytokine signaling pathways and clinical outcomes in early-stage lung cancer patients. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018 , 155, 2635-2645.e15	1.5	2
101	Natural History of Ground-Glass Lesions Among Patients With Previous Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018 , 105, 1671-1677	2.7	11
100	Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy. <i>Cancer Medicine</i> , 2018 , 7, 2405-2414	4.8	16
99	Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. <i>Modern Pathology</i> , 2018 , 31, 947-955	9.8	35
98	Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018 , 105, 1621-1626	2.7	4
97	Clinicoradiographic Predictors of Aggressive Biology in Lung Cancer With Ground Glass Components. <i>Annals of Thoracic Surgery</i> , 2018 , 106, 235-241	2.7	8
96	Enhanced Recovery Decreases Pulmonary and Cardiac Complications After Thoracotomy for Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018 , 106, 272-279	2.7	98
95	Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 779-791	8.9	39
94	RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 341-350	12.9	25
93	Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches 2018 , 6, 48		76
92	Predictors of survival after resection of primary sarcomas of the chest wall-A large, single-institution series. <i>Journal of Surgical Oncology</i> , 2018 , 118, 518-524	2.8	9
91	Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. <i>Oncology</i> , 2018 , 94, 345-353	3.6	
90	Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. <i>Oncotarget</i> , 2018 , 9, 14268-14284	3.3	9
89	Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing. <i>Cancer</i> , 2018 , 124, 1061-1069	6.4	8
88	Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018 , 105, 418-424	2.7	14
87	HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells. <i>Annals of Thoracic Surgery</i> , 2018 , 105, 363-370	2.7	8

86	Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial. <i>British Journal of Cancer</i> , 2018 , 118, 331-337	8.7	6
85	Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial. <i>Targeted Oncology</i> , 2018 , 13, 99-106	5	8
84	Occult stage IIIA-N2 patients have excellent overall survival with initial surgery. <i>Journal of Thoracic Disease</i> , 2018 , 10, 6670-6676	2.6	5
83	Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer. <i>Journal of Translational Medicine</i> , 2018 , 16, 328	8.5	7
82	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1818-1831	8.9	73
81	Perioperative Outcomes for Stage I Non-Small Cell Lung Cancer: Differences Between Men and Women. <i>Annals of Thoracic Surgery</i> , 2018 , 106, 1499-1503	2.7	4
80	Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in -Mutant NSCLC. <i>Clinical Cancer Research</i> , 2018 , 24, 6195-6203	12.9	178
79	Oesophageal preservation in locally advanced oesophageal cancer. <i>Lancet Oncology, The</i> , 2018 , 19, e43021.7	1.7	1
78	Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy. <i>Surgery</i> , 2017 , 161, 1246-1254	3.6	14
77	Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017 , 122, 274-280	5.3	27
76	Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. <i>Cancer Immunology Research</i> , 2017 , 5, 319-329	12.5	9
75	Consolidative local therapy in oligometastatic patients - AuthorsReply. <i>Lancet Oncology, The</i> , 2017 , 18, e62	21.7	
74	Salvage pulmonary resection after stereotactic body radiotherapy: A feasible and safe option for local failure in selected patients. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017 , 154, 689-699	1.5	37
73	Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors. <i>Cell Reports</i> , 2017 , 19, 1669-1684	10.6	55
72	Polytetrafluoroethylene or Acellular Dermal Matrix for Diaphragmatic Reconstruction?. <i>Annals of Thoracic Surgery</i> , 2017 , 103, 1710-1714	2.7	7
71	Perioperative Outcomes of Patients Undergoing Lobectomy on Clopidogrel. <i>Annals of Thoracic Surgery</i> , 2017 , 104, 1821-1828	2.7	5
70	Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy. <i>Oncolimmunology</i> , 2017 , 7, e1376156	7.2	11
69	Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. <i>Cancer</i> , 2017 , 123, 4106-4113	6.4	61

68	Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. <i>British Journal of Cancer</i> , 2017 , 117, 648-655	8.7	20
67	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. <i>Cancer Discovery</i> , 2017 , 7, 1088-1097	24.4	105
66	Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: A large single-institutional cohort study. <i>Advances in Radiation Oncology</i> , 2017 , 2, 316-324	3.3	8
65	Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2017 , 112, 90-95	5.9	128
64	Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 375-382	8.9	43
63	Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 97, 770-777	4	11
62	Salvage esophagectomy for persistent or recurrent disease after definitive chemoradiation. <i>Annals of Cardiothoracic Surgery</i> , 2017 , 6, 144-151	4.7	19
61	DNA methylation intratumor heterogeneity in localized lung adenocarcinomas. <i>Oncotarget</i> , 2017 , 8, 21994-22002	3.3	20
60	Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma. <i>Oncotarget</i> , 2017 , 8, 79356-79365	3.3	2
59	Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activities. <i>Oncotarget</i> , 2017 , 8, 102150-102160	3.3	160
58	Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2017 , 29, 408-415	1.7	18
57	Clinical Prediction of Pathologic Complete Response in Superior Sulcus Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2016 , 101, 211-7	2.7	8
56	The Influence of Reconstructive Technique on Perioperative Pulmonary and Infectious Outcomes Following Chest Wall Resection. <i>Annals of Thoracic Surgery</i> , 2016 , 102, 1653-1659	2.7	22
55	Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. <i>Lancet Oncology, The</i> , 2016 , 17, 1672-1682	21.7	548
54	Genomic heterogeneity of multiple synchronous lung cancer. <i>Nature Communications</i> , 2016 , 7, 13200	17.4	85
53	Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients. <i>Clinical Cancer Research</i> , 2016 , 22, 6278-6289	12.9	96
52	Results of Postdischarge Nursing Telephone Assessments: Persistent Symptoms Common Among Pulmonary Resection Patients. <i>Annals of Thoracic Surgery</i> , 2016 , 102, 276-81	2.7	16
51	Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. <i>Oncotarget</i> , 2016 , 7, 3548-58	3.3	89

50	Accumulation of RNA-dependent protein kinase (PKR) in the nuclei of lung cancer cells mediates radiation resistance. <i>Oncotarget</i> , 2016 , 7, 38235-38242	3.3	5
49	Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer. <i>Cancer</i> , 2016 , 122, 917-28	6.4	59
48	A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 173-9	7.3	6
47	Genomic Landscape Established by Allelic Imbalance in the Cancerization Field of a Normal Appearing Airway. <i>Cancer Research</i> , 2016 , 76, 3676-83	10.1	28
46	Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location. <i>Annals of Thoracic Surgery</i> , 2016 , 101, 1075-80; Discussion 1080-1	2.7	14
45	Predictive biomarkers in precision medicine and drug development against lung cancer. <i>Chinese Journal of Cancer</i> , 2015 , 34, 295-309		29
44	Endoscopic Ultrasound Estimates for Tumor Depth at the Gastroesophageal Junction Are Inaccurate: Implications for the Liberal Use of Endoscopic Resection. <i>Annals of Thoracic Surgery</i> , 2015 , 100, 1812-6	2.7	30
43	SABR vs surgery for NSCLC in the media. <i>Lancet Oncology, The</i> , 2015 , 16, e422	21.7	6
42	Genetic variation in the TNF/TRAF2/ASK1/p38 kinase signaling pathway as markers for postoperative pulmonary complications in lung cancer patients. <i>Scientific Reports</i> , 2015 , 5, 12068	4.9	10
41	Time to treatment as a quality metric in lung cancer: Staging studies, time to treatment, and patient survival. <i>Radiotherapy and Oncology</i> , 2015 , 115, 257-63	5.3	78
40	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. <i>Cancer Letters</i> , 2015 , 357, 179-185	9.9	68
39	Limitations of 18F-2-deoxy-D-glucose positron emission tomography in N1 detection in patients with pathologic stage II-N1 and implications for management. <i>Annals of Thoracic Surgery</i> , 2015 , 99, 414-20	2.7	7
38	Expression of sulfotransferase SULT1A1 in cancer cells predicts susceptibility to the novel anticancer agent NSC-743380. <i>Oncotarget</i> , 2015 , 6, 345-54	3.3	9
37	RNA-dependent protein kinase (PKR) depletes nutrients, inducing phosphorylation of AMP-activated kinase in lung cancer. <i>Oncotarget</i> , 2015 , 6, 11114-24	3.3	7
36	A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2015 , 6, 45-52	2.8	15
35	Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. <i>Lung Cancer</i> , 2014 , 85, 88-93	5.9	48
34	Thoracoscopic lobectomy is associated with improved short-term and equivalent oncological outcomes compared with open lobectomy for clinical Stage I non-small-cell lung cancer: a propensity-matched analysis of 963 cases. <i>European Journal of Cardio-thoracic Surgery</i> , 2014 , 46, 607-13	3	89
33	Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	74

32	Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 90, 850-7	4	49
31	Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380. <i>Bioorganic and Medicinal Chemistry</i> , 2014 , 22, 5234-40	3.4	7
30	Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. <i>Science</i> , 2014 , 346, 256-9	33.3	659
29	Signet ring cells in esophageal adenocarcinoma predict poor response to preoperative chemoradiation. <i>Annals of Thoracic Surgery</i> , 2014 , 98, 1064-71	2.7	41
28	Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone". <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 88, 1120-8	4	167
27	Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 1139-44	7.3	13
26	Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. <i>JAMA Surgery</i> , 2014 , 149, 1244-53	5.4	166
25	Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. <i>Lancet Oncology</i> , 2014 , 15, e42-50	21.7	210
24	Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma. <i>Oncotarget</i> , 2014 , 5, 6584-93	3.3	12
23	IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 2864-73	6.1	47
22	Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 222-8	8.9	72
21	A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 82, 1967-72	4	64
20	Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 825-32	8.9	167
19	Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. <i>Annals of Thoracic Surgery</i> , 2010 , 90, 892-8; discussion 898-9	2.7	41
18	Influence of Age on Choice of Therapy and Surgical Outcomes in Patients with Nonsmall Cell Lung Cancer. <i>American Surgeon</i> , 2009 , 75, 598-604	0.8	5
17	Adenoviral endoplasmic reticulum-targeted mda-7/interleukin-24 vector enhances human cancer cell killing. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 2528-35	6.1	18
16	Impact of Induction Chemotherapy and Preoperative Chemoradiotherapy on Operative Morbidity and Mortality in Patients with Locoregional Adenocarcinoma of the Stomach or Gastroesophageal Junction. <i>Annals of Surgical Oncology</i> , 2007 , 14, 1305-1311	3.1	4
15	The supercharged microvascular jejunal interposition. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2007 , 19, 56-65	1.7	27

14	Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). <i>Annals of Surgery</i> , 2005 , 241, 810-7; discussion 817-20	7.8	122
13	2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. <i>Cancer</i> , 2004 , 101, 1776-85	6.4	217
12	Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. <i>Annals of Thoracic Surgery</i> , 2004 , 78, 1152-60; discussion 1152-60	2.7	274
11	Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003 , 57, 120-7	4	64
10	Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. <i>Clinical Cancer Research</i> , 2003 , 9, 93-101	12.9	146
9	Genetic and immunologic therapies for lung cancer. <i>Seminars in Oncology</i> , 2002 , 29, 95-101	5.5	25
8	Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2002 , 123, 175-83	1.5	211
7	p53 Gene therapy for lung cancer. <i>Current Oncology Reports</i> , 2002 , 4, 334-40	6.3	21
6	Clinical update of Ad-p53 gene therapy for lung cancer. <i>Surgical Oncology Clinics of North America</i> , 2002 , 11, 521-35	2.7	32
5	A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. <i>Cancer</i> , 2001 , 92, 279-86	6.4	108
4	Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53). <i>Cancer Gene Therapy</i> , 2000 , 7, 530-6	5.4	59
3	Gastroesophageal junction adenocarcinoma. <i>Current Treatment Options in Oncology</i> , 2000 , 1, 387-98	5.4	14
2	Gene therapy in lung cancer. <i>Current Oncology Reports</i> , 2000 , 2, 64-70	6.3	11
1	Influence of lymph node dissection on survival in esophageal cancer. <i>Journal of Surgical Oncology</i> , 1998 , 69, 117-8	2.8	1